MX2022016367A - Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. - Google Patents
Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.Info
- Publication number
- MX2022016367A MX2022016367A MX2022016367A MX2022016367A MX2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A
- Authority
- MX
- Mexico
- Prior art keywords
- diarrhea
- treatment
- methods
- chemotherapy
- compositions
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 238000002512 chemotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000037427 ion transport Effects 0.000 abstract 2
- 229920001393 Crofelemer Polymers 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010000059 abdominal discomfort Diseases 0.000 abstract 1
- 229940047615 crofelemer Drugs 0.000 abstract 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos para tratar la diarrea mediante la administración a un paciente que lo necesite, de un inhibidor del transporte de iones de cloruro en una cantidad suficiente para tratar la diarrea. El tratamiento de la diarrea incluye el tratamiento de la diarrea así como del dolor, malestar abdominal y otros síntomas asociados con la diarrea. En una modalidad, el inhibidor del transporte de iones de cloruro es crofelemer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2020/038691 WO2021257089A1 (en) | 2020-06-19 | 2020-06-19 | Methods and compositions for treating chemotherapy-induced diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016367A true MX2022016367A (es) | 2023-01-30 |
Family
ID=79268234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016367A MX2022016367A (es) | 2020-06-19 | 2020-06-19 | Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4168027A4 (es) |
| JP (1) | JP2023538186A (es) |
| KR (1) | KR20230027226A (es) |
| AU (1) | AU2020454132A1 (es) |
| BR (1) | BR112022025741A2 (es) |
| CA (1) | CA3182864A1 (es) |
| IL (1) | IL299028A (es) |
| JO (1) | JOP20220339A1 (es) |
| MX (1) | MX2022016367A (es) |
| PH (1) | PH12022553514A1 (es) |
| WO (1) | WO2021257089A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115089592B (zh) * | 2022-05-21 | 2024-02-27 | 复旦大学 | 多重酪氨酸激酶在制备抑制肠道病毒71型嗜神经性病毒药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010303577B2 (en) * | 2009-10-06 | 2015-10-22 | Napo Pharmaceuticals, Inc. | Methods of treating diseases with proanthocyanidin oligomers such as crofelemer |
| EP2632550B1 (en) * | 2010-10-31 | 2017-05-03 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating hiv-associated diarrhea |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| US20180264061A1 (en) * | 2015-01-09 | 2018-09-20 | Jaguar Animal Health | Methods of Treating Diarrhea in Companion Animals |
| JP2020513410A (ja) * | 2016-12-06 | 2020-05-14 | カレイド・バイオサイエンシズ・インコーポレイテッド | グリカンポリマーおよびその関連方法 |
| JOP20190275B1 (ar) * | 2017-05-31 | 2024-12-22 | Napo Pharmaceuticals Inc | طرق وتركيبات لعلاج اضطراب إسهال خِلقي |
-
2020
- 2020-06-19 MX MX2022016367A patent/MX2022016367A/es unknown
- 2020-06-19 CA CA3182864A patent/CA3182864A1/en active Pending
- 2020-06-19 BR BR112022025741A patent/BR112022025741A2/pt unknown
- 2020-06-19 JP JP2022578560A patent/JP2023538186A/ja active Pending
- 2020-06-19 WO PCT/US2020/038691 patent/WO2021257089A1/en not_active Ceased
- 2020-06-19 EP EP20940856.6A patent/EP4168027A4/en active Pending
- 2020-06-19 IL IL299028A patent/IL299028A/en unknown
- 2020-06-19 AU AU2020454132A patent/AU2020454132A1/en active Pending
- 2020-06-19 JO JOP/2022/0339A patent/JOP20220339A1/ar unknown
- 2020-06-19 KR KR1020237002209A patent/KR20230027226A/ko active Pending
- 2020-06-19 PH PH1/2022/553514A patent/PH12022553514A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL299028A (en) | 2023-02-01 |
| KR20230027226A (ko) | 2023-02-27 |
| JOP20220339A1 (ar) | 2023-01-30 |
| EP4168027A4 (en) | 2024-04-03 |
| BR112022025741A2 (pt) | 2023-01-03 |
| CA3182864A1 (en) | 2021-12-23 |
| EP4168027A1 (en) | 2023-04-26 |
| WO2021257089A1 (en) | 2021-12-23 |
| PH12022553514A1 (en) | 2024-06-03 |
| JP2023538186A (ja) | 2023-09-07 |
| AU2020454132A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382400B (es) | Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea. | |
| ECSP13012650A (es) | Métodos y composiciones para tratar diarrea asociada con vih | |
| PY2126213A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| ECSP21080528A (es) | Compuestos antivirales que contienen nitrilo | |
| MX2024002561A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres. | |
| CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2021005240A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
| CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
| CO2024000880A2 (es) | Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con at2r y/o señalización mediada por at2r | |
| CL2024003729A1 (es) | Terapia combinada de agente activo anti-pd-1, agente activo anti-tim-3 y agente activo anti-lag-3 para tratar cáncer. | |
| MX2022016367A (es) | Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| CL2022003634A1 (es) | Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| CL2024003535A1 (es) | Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia | |
| CL2023000698A1 (es) | Composiciones y metodos para el tratamiento de distrofias musculares | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a | |
| MX2024012368A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2023005829A (es) | Combinaciones farmaceuticas para tratar el cancer. | |
| MX2025005720A (es) | Inhibidores de la tirosina-cinasa 2 (tyk2) | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| CO6771411A2 (es) | Metodos y composiciones para tratar diarrea asociada al vih | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| MX2024014419A (es) | Peptidos y metodos para usar en el tratamiento del dolor |